scholarly journals Correction: Stagnation of histopathological improvement is a predictor of hepatocellular carcinoma development after hepatitis C virus eradication

PLoS ONE ◽  
2018 ◽  
Vol 13 (7) ◽  
pp. e0201423
Author(s):  
Hiroyuki Motoyama ◽  
Akihiro Tamori ◽  
Shoji Kubo ◽  
Sawako Uchida-Kobayashi ◽  
Shigekazu Takemura ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Virus Eradication

Clinical features and prognosis in patients with hepatocellular carcinoma that developed after hepatitis C virus eradication with interferon therapy

2011 ◽  
Vol 46 (6) ◽  
pp. 799-808 ◽  
Author(s):  
Yuko Nagaoki ◽  
Hiroshi Aikata ◽  
Daisuke Miyaki ◽  
Eisuke Murakami ◽  
Yoshimasa Hashimoto ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Clinical Features ◽  
Interferon Therapy ◽  
Virus Eradication

Impact of Hepatitis C Virus Eradication on the Clinical Outcome of Patients with Hepatitis C Virus-Related Advanced Hepatocellular Carcinoma Treated with Sorafenib

Oncology ◽  
2017 ◽  
Vol 92 (6) ◽  
pp. 335-346 ◽  
Author(s):  
Tomokazu Kawaoka ◽  
Hiroshi Aikata ◽  
Yuji Teraoka ◽  
Yuki Inagaki ◽  
Fumi Honda ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Clinical Outcome ◽  
Advanced Hepatocellular Carcinoma ◽  
Virus Eradication

scholarly journals Impact of hepatitis C virus eradication on hepatocellular carcinoma rates

2017 ◽  
Vol 10 (3) ◽  
pp. 75-78
Author(s):  
Philippe J. Zamor ◽  
Mark W. Russo
Keyword(s):  
Hepatocellular Carcinoma ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Virus Eradication

PNPLA3 and HLA-DQB1 polymorphisms are associated with hepatocellular carcinoma after hepatitis C virus eradication

2020 ◽  
Vol 55 (12) ◽  
pp. 1162-1170 ◽  
Author(s):  
Daiki Miki ◽  
Tomoyuki Akita ◽  
Akemi Kurisu ◽  
Tomokazu Kawaoka ◽  
Tomoaki Nakajima ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Virus Eradication

Short-term risk of hepatocellular carcinoma after hepatitis C virus eradication following direct-acting anti-viral treatment

2017 ◽  
Vol 47 (1) ◽  
pp. 104-113 ◽  
Author(s):  
E. Ogawa ◽  
N. Furusyo ◽  
H. Nomura ◽  
K. Dohmen ◽  
N. Higashi ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Short Term ◽  
Virus Eradication ◽  
Direct Acting

scholarly journals Post-treatment Mac-2-Binding Protein is a Useful Predictor of Hepatocellular Carcinoma Development after Hepatitis C Virus Eradication

2021 ◽  
Author(s):  
Shunsuke Sato ◽  
Hironori Tsuzura ◽  
Yuji Kita ◽  
Yuji Ikeda ◽  
Daishi Kabemura ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Liver Fibrosis ◽  
Binding Protein ◽  
Virologic Response ◽  
Virus Eradication ◽  
Direct Acting Antiviral ◽  
Noninvasive Biomarker ◽  
Direct Acting

Abstract Background and aims: Recent advances of direct-acting antiviral drugs for hepatitis C virus (HCV) have dramatically improved the sustained virologic response (SVR) rate, but hepatocellular carcinoma (HCC) development not rarely occurs even in patients who achieve an SVR. Wisteria floribunda agglutinin-positive Mac-2-binding protein (WFA+-M2BP) was recently developed as a noninvasive biomarker of liver fibrosis. However, the association between the WFA+-M2BP level and HCC development after the achievement of an SVR is unclear. Methods: We examined the association between WFA+-M2BP and HCC development in 552 HCV patients who achieved an SVR (Interferon [IFN]-based therapy, n=228; IFN-free therapy, n=294). Results: Multivariate analysis revealed that a high WFA+-M2BP level at SVR week 24 after treatment (SVR24) (hazard ratio [HR]=1.215, P=0.020), low platelet counts (HR=0.876, P=0.037) and old age (HR=1.073, P=0.012) were independent risk factors for HCC development regardless of the treatment regimen. Receiver operator characteristics curve analysis revealed that an WFA+-M2BP level at SVR24 of ≥1.62 cut off index (COI) was the cut-off value for the prediction of HCC development (adjusted HR = 12.565, 95% CI 3.501-45.092, P<0.001). The 3- and 5-year cumulative incidences of HCC were 0.7% and 0.7% in patients with low WFA+-M2BP at SVR24 (<1.62 COI), and 4.8% and 12.4% in patients with high WFA+-M2BP (≥1.62 COI) were, respectively (P<0.001).Conclusion: The assessment of liver fibrosis using the WFA+-M2BP level at SVR24 is a useful predictor of HCC development after HCV eradication even in the IFN-free therapy era.

Sign in / Sign up

Export Citation Format

Share Document